Results 51 to 60 of about 106 (72)

Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial. [PDF]

open access: yesNat Commun
Vaz-Salgado MÁ   +7 more
europepmc   +1 more source

Megakaryocytic Differentiation Regulates the Permissiveness and Antiviral Response of the Megakaryocytic Erythroid Progenitor to Dengue Virus. [PDF]

open access: yesInt J Mol Sci
Cruz-Hernández DS   +11 more
europepmc   +1 more source

PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines. [PDF]

open access: yesCells, 2018
Carrasco-Garcia E   +9 more
europepmc   +1 more source

Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma. [PDF]

open access: yesOncotarget, 2015
González-Gómez P   +7 more
europepmc   +1 more source

Needle-track metastasis in diffuse intrinsic pontine glioma: Need for a standardized surgical strategy? [PDF]

open access: yesNeurooncol Adv
Nussbaumer G   +45 more
europepmc   +1 more source

Bevacizumab for the treatment of glioblastoma. [PDF]

open access: yesClin Med Insights Oncol, 2013
Gil-Gil MJ, Mesia C, Rey M, Bruna J.
europepmc   +1 more source

Primer consenso mexicano sobre recomendaciones de la atención multidisciplinaria del paciente con glioblastoma multiforme (GBM). Grupo Interdisciplinar Mexicano de Investigación en Neurooncología (GIMINO)

open access: yes
El GBM es uno de los tumores más agresivos y con peor pronóstico del sistema nervioso central. Los tratamientos aplicados hasta el momento han logrado aumentar sensiblemente la supervivencia de estos pacientes, dependiendo de la edad, el estado cognitivo
Green Renner, Dan   +17 more
core  

Role of receptor tyrosine kinases and their ligands in glioblastoma. [PDF]

open access: yesCells, 2014
Carrasco-García E   +2 more
europepmc   +1 more source

Recurrent malignant gliomas. [PDF]

open access: yesSemin Radiat Oncol, 2014
Kirkpatrick JP, Sampson JH.
europepmc   +1 more source

Home - About - Disclaimer - Privacy